Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Forward Ventures
AddedFeb 13, 2024
UpdatedJun 28, 2026
Forward Ventures

Forward Ventures

Operating

Forward Ventures: A venture capital firm specializing in biological sciences.

Location
San Diego, CA, US
Founded
1993
Firm
Compare
Portfolio
Employees

Investments

Viracta Therapeutics
Viracta Therapeutics
Public

Total Raised

$194.9M

Rounds

11

Series B$18.4MApril 2017
Series B$13MMarch 2012
Series B$12MApril 2010
Series A$20MNovember 2007
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Public

Total Raised

$803.6M

Rounds

16

Series C$80MAugust 2015
Series B$26.6MAugust 2013
Series A$9MMarch 2010
Series A$40MApril 2007
Ambit Biosciences
Ambit Biosciences
Acquired

Total Raised

$215.7M

Rounds

11

Series Unknown$50MNovember 2012
Series D$30MJune 2011
Series D$49.3MNovember 2007
Series C$31MMay 2005
Tioga Pharmaceuticals
Tioga Pharmaceuticals
Public

Total Raised

$57M

Rounds

5

Series Unknown$18MFebruary 2010
Series A$24MJanuary 2006
Altair Therapeutics
Altair Therapeutics

Total Raised

$23.5M

Rounds

2

Series B$17MFebruary 2010
Asteres
Asteres

Total Raised

$8M

Rounds

4

Series C$4MNovember 2007
Sequel Pharmaceuticals
Sequel Pharmaceuticals

Total Raised

$25.4M

Rounds

4

Series A$20MSeptember 2007
Sanarus Medical
Sanarus Medical
Acquired

Total Raised

$70.9M

Rounds

5

Series E$15MFebruary 2007
Series D$23MApril 2005
Series C$19.1MNovember 2003
Kemia
Kemia

Total Raised

$100M

Rounds

4

Series C$31MAugust 2006
Series B$33.5MMarch 2004
Series A$16.5MNovember 2002
Acorda Therapeutics
Acorda Therapeutics
Public

Total Raised

$151.6M

Rounds

12

Series B$55.3MMay 2003
Dynavax Technologies
Dynavax Technologies
Public

Total Raised

$1.4B

Rounds

19

Series D$34.8MApril 2002